Introduction: Morphological and metabolic complications in HIV patients on antiretroviral therapy remain a challenge. While new cases of lipoatrophy (LA) disappear, irreducible central lipohypertrophy (LH) and metabolic complications require highly specialized management. We described a day hospital dedicated to lipodystrophy (LD) and metabolic disorders in HIV patients on treatment in Geneva, Switzerland, with a focus on LH. . In this population, mean age was 49.1 years and 53.6% were male. HIV viral load was B50 cp/ml in 87% of patients. Mean body mass index was 24.6 kg/m 2 . Mean waist to hip ratio (WHR) was 0.98 for males and 0.89 for females. A total of 9.8%, 29.5% and 35% of patients had abnormal levels of total cholesterol (]6.5 mmol/L), triglycerides ( ]2.0 mmol/L) and HDL cholesterol ( 51.0 mmol/L), respectively. Mean fasting glycaemia was 5.7 mmol/L and HbA1c was 6% in 10.5% of patients. Vitamin-D level was B75 nmol/L in 70.7% of patients. Respectively 31.2% and 12.1% of patients had osteopenia and osteoporosis on the spine and 44.8% and 6.6% on the hip neck. Factors associated with a VAT]130 cm 2 included male gender (OR 3.7 [95% CI 1.7Á8.2] pB0.001), triglycerides ]2 mmol/L (OR 2.6 [95% CI 1.3Á5.4] P B0.01) and increase in BMI category (OR 1.8 [95% CI 1.2Á2.8] pB0.01). Conclusions: Lipohypertrophy is a prevalent feature of fat redistribution among HIV patients on treatment. Risk factors for LH include male gender, dyslipidemia and overweight. Glucose impairment and bone disorders are also common. A multidisciplinary approach is important to identify and promptly address these disorders.
